Leslie Trigg Sells 10,227 Shares of Outset Medical, Inc. (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 10,227 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $1.29, for a total transaction of $13,192.83. Following the transaction, the chief executive officer now owns 894,624 shares in the company, valued at $1,154,064.96. The trade was a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Leslie Trigg also recently made the following trade(s):

• On Friday, November 15th, Leslie Trigg sold 5,645 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total transaction of $4,516.00.

Outset Medical Trading Down 10.9 %

OM opened at $0.98 on Thursday. The company has a debt-to-equity ratio of 4.12, a quick ratio of 5.04 and a current ratio of 6.49. Outset Medical, Inc. has a twelve month low of $0.44 and a twelve month high of $5.27. The firm’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.50. The firm has a market cap of $51.49 million, a PE ratio of -0.36 and a beta of 2.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OM. Los Angeles Capital Management LLC acquired a new stake in shares of Outset Medical during the second quarter worth $731,000. Acadian Asset Management LLC boosted its stake in Outset Medical by 5.2% in the 2nd quarter. Acadian Asset Management LLC now owns 819,563 shares of the company’s stock worth $3,154,000 after purchasing an additional 40,321 shares during the period. Ground Swell Capital LLC bought a new position in Outset Medical during the 2nd quarter worth about $49,000. Massachusetts Financial Services Co. MA raised its stake in shares of Outset Medical by 118.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,538,859 shares of the company’s stock valued at $5,925,000 after purchasing an additional 834,663 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Outset Medical in the second quarter valued at about $49,000.

Analysts Set New Price Targets

Separately, Royal Bank of Canada restated a “sector perform” rating and issued a $3.00 price target on shares of Outset Medical in a research report on Tuesday.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.